Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of

Status Not yet recruiting

Clinical Trial Summary

The investigators evaluate the effects of intracoronary and intravenous administration of nicorandil on cardiac sympathetic nerve activity and distribution in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

Clinical Trial Description

Reperfusion injury might occur in patients with acute ST segment elevation myocardial infarction undergoing the primary percutaneous coronary intervention(P-PCI),characterized by myocardial stunning, reperfusion-induced arrhythmia, microvascular dysfunction and injury of cardiac sympathetic nerve, etc. Nicorandil is an antianginal agent with a dual mechanism of action: nitrate and K+ATP channel opener. The nitrate action causes vasodilation of systemic veins and epicardial coronary arteries, while the adenosine triphosphate (ATP)-sensitive potassium channel opener action causes vasodilation of peripheral and coronary resistance arterioles. Nicorandil not only decreases preload and afterload but also increases coronary blood flow. The study will compare the effectiveness between nicorandil and placebo of preventing the reperfusion injury especially injury of cardiac sympathetic nerve in patients with acute ST segment elevation myocardial infarction undergoing the P-PCI.It is intended that before reperfusion injury ,nicorandil which was early used by intracoronary injection could prevent and release the microcirculatory spasm, release the coronary microvascular endothelial swelling,decrease embolism of atherosclerotic debris and thrombus formation,moreover,it could reduces the release of norepinephrine from sympathetic endings of the heart directly.So,it could decrease the phenomenon of no-reflow/slow reflow,reperfusion-induced arrhythmia and injury of cardiac sympathetic nerve. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04826497
Study type	Interventional
Source	Xuzhou Central Hospital
Contact	chunguang Feng, PhD
Phone	+8618936376559
Email	fcg999@163.com
Status	Not yet recruiting
Phase	Phase 4
Start date	April 2021
Completion date	February 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05196659` - Collaborative Quality Improvement (C-QIP) Study	N/A
Completed	`NCT05088291` - Application of a New X-ray Protective Device in Coronary Interventional Therapy
Completed	`NCT03076801` - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?	N/A
Completed	`NCT04584645` - A Digital Flu Intervention for People With Cardiovascular Conditions	N/A
Not yet recruiting	`NCT04995159` - Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System	N/A
Recruiting	`NCT02967718` - Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome	N/A
Completed	`NCT02888652` - Study on the Registration of Coronary Heart Disease Patients Undergoing PCI
Terminated	`NCT02045134` - Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery	N/A
Completed	`NCT02163044` - The Hellenic Postprandial Lipemia Study (HPLS)
Active, not recruiting	`NCT02244853` - Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease	N/A
Terminated	`NCT01906957` - Cognition and Exercise Training	N/A
Completed	`NCT01920009` - Impact of Motivational Interviews Within Pharmacy Care Upon Adherence to Cardiovascular Medicines	N/A
Completed	`NCT02753829` - Home-based Cardiovascular Rehabilitation, Maintenance Phase, in Subjects With Coronary Artery Disease	N/A
Completed	`NCT02440893` - Understanding the Effect of Metformin on Corus CAD (or ASGES)
Completed	`NCT01826552` - Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent	Phase 4
Recruiting	`NCT01689688` - Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography	N/A
Completed	`NCT01779401` - Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients	N/A
Recruiting	`NCT01456364` - Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing	Phase 4
Recruiting	`NCT01462799` - COR-PRIM: Problem-based Learning (PBL) After Coronary Heart Disease (CHD) - Long-term Evaluation in Primary Care of Self-care	N/A
Completed	`NCT01486030` - Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms